Sdi Dividends - SDI

Best deals to access real time data!
Level 2 Basic Monthly Subscription for only ~~£62.08~~
Silver Monthly Subscription for only ~~£17.37~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Sdi Group Plc	SDI	London	Ordinary Share	GB00B3FBWW43	ORD 1P

	Price Change	Price Change %	Stock Price	Last Trade
	6.80	7.91%	92.80	16:04:37

Open Price	Low Price	High Price	Close Price	Previous Close
86.50	86.50	92.80	92.80	86.00

more quote information »

Industry Sector
ELECTRONIC & ELECTRICAL EQUIPMENT

Sdi SDI Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
27/03/2007	Final	SEK	6	31/12/2005	31/12/2006	29/03/2007	02/04/2007	01/01/1970	6

Top Dividend Posts

Date	Subject
03/12/2020 23:16	fillspectre: Hastings - are we still on for a SDI trading update before Christmas here? Do those unaudited figures quoted in today's RNS for the SDI Group match your expectations? At 31 October 2020, the Group had cash of £3.4 million (unaudited) and net debt of £0.3 million (unaudited). How much of the £5.0 million undrawn bank facility do you think they will use? Do you think the Group holds enough fire power to continue the acquisition hunt over the next five months. How much cash do you think the Group is now throwing off into Mike's buying pot? Fils Read Full Thread Follow Reply
03/12/2020 12:02	rivaldo: Finncap have issued a 12 page note on the acquisition, with as stated an increased 125p target price - here's just the summary: "Acquisition in lockdown –14% accretive in first full year SDI has announced the acquisition of Monmouth Scientific, paying c.£5.8m for the business(including a £2.1m earn-out based on FY 2021E adjusted EBIT). Monmouth manufactures biological safety cabinets, amongst other air flow products, which are seeing strong demand due to the dynamicgrowth in PCR testing capacity for COVID-19. The acquisition is funded from cash and SDI’s existing debt facility,with net debt at year-end now expected to be c.£4.3m. We expect the acquisition to be immediately EPS enhancing (6%) and to be c.14% accretive to EPS in FY 2022. We raise our target price by 14% to 125p to reflect the accretion and rolling forward the multiples to FY 2022, which would imply the stock trading onFY 2022P/E of 26.7x, EV/EBIT of 20.8x and EV/EBITDA of16.6x. The acquisition. Monmouth Scientific is a manufacturer of biological safety cabinets, fume cupboards, laminar flow cabinets and cleanrooms for end-markets including Laboratory, Pharmaceutical and Industrial Analytical Research,as well as Industrial, Electronics, Medical and Education establishments. Based in the UK, Monmouth had FY 2020 revenues of £6.2m, 20% of which were exported, with adjusted EBIT of c.£0.4m.It is currently benefiting from a surge in demand for its biological safety cabinets, which are typically used to house PCR instruments – the backbone of COVID-19 testing. The company expects this to continue for the rest of its financial year,resulting in c.37% FY revenue growth (c.£8.5m) andthe reason for an earn-out. Consideration. SDI is paying c.£5.8m to acquire Monmouth Scientific, which implies 0.7x and 3.6x prospectiveFY 2021sales and EBIT,respectively. The acquisition is funded from cash and existing debt facilities, with year-end net debt of c.£4.3m expected. Included in this price is a post-completion payment for net current assets of no more than £1.6m, of which c.£0.6m is expected to be cash in the business. Strategic rationale. The acquisition is in line with the Group’s strategy of acquiring businesses with complementary technology products. Monmouth’s quality is reflected in its customer list, which includes some of the UK’s leading private and government organisations, such as Mercedes F1, BAE Systems, the MoD and the NHS. Forecasts. We forecast Monmouth Scientific to contribute £3.5m and £0.3m to FY 2021 revenue and adjusted EBIT, respectively, rising to £7.0m and £0.8m in FY 2022. We expect Monmouth Scientific to be 6% accretive to adjusted fully diluted EPS in the current year and 14% in FY 2022. Valuation. We raise our target price by 14% to 125p (from 110p), reflecting the accretion to earnings, rolling forward the target multiples to FY 2022 and taking into consideration its peer group (eg. Judges Scientific) multiples." Read Full Thread Follow Reply
03/12/2020 09:14	rivaldo: SDI say the acquired company will be "immediately earnings-enhancing". Monmouth made £800k EBIT in the last 6 months alone, and the earn-out is based on a maximum of £1.9m EBIT. Besides, it's evident from the RNS that SDI are stripping out "non-recurring items" and adjusting Monmouth's cost base, so the historic figures - even before this year's huge surge in profits - won't be relevant. SDI's management have proven their ability in their record of acquisition integration to date. I trust them to continue. Read Full Thread Follow Reply
11/11/2020 08:47	rivaldo: Good to see SDI continue to rise nicely. All this extra global investment and attention on the world of laboratories and scientific instrumentation has to be good news. As regards the Pfizer vaccine, it seems there will be a big need for clinical/medical freezers (assuming it succeeds, which imo is still a very big question). I'm pretty sure SDI don't have any involvement in this area (Fistreem do vacuum ovens!), but happy to be corrected. Read Full Thread Follow Reply
01/9/2020 11:40	rivaldo: In case anyone missed the RNS last week, SDI's AGM is to be on 23rd September, and there will be a live presentation and Q&A via InvestorMeet - so register because they're really good! Https://www.investegate.co.uk/sdi-group-plc--sdi-/rns/posting-of-ar-a-and-notice-of-agm---replacement/202008261649452513X/ Read Full Thread Follow Reply
10/8/2020 07:58	rivaldo: Techinvest had an introductory feature on SDI in this month's issue, in the "Market Miscellany" column. Above all, they conclude that SDI are a Buy - and that they will "write more next month". There's nothing that's new to long-term holders here. But they note that SDI are well positioned to benefit from "the global expansion of automation and in-process instruments, as well as medical and pharmaceutical research". And that they like buy and build models like SDI's, which offers strong potential growth as a consolidator in a targeted niche. Read Full Thread Follow Reply
21/7/2020 07:29	rivaldo: Finncap have introduced new forecasts and a very nice 100p target price. They support the theory that SDI will report revenue and profits "at least" in line with last year, i.e likely better than but at worst the same as. They go for 3.7p EPS rising to 4.1p EPS next year - though of course SDI are flagging more acquisitions, which should enhance earnings further. It's interesting to see JDG's trading statement, which is also out (conveniently) today. They seem much more downbeat than SDI, and seem to have lost out all round from the pandemic, whereas SDI have benefited from COVID-19 in a majority of their divisions and are actually thriving in some cases. Read Full Thread Follow Reply
09/6/2020 14:31	tjbird: SDI Group (SDI) : Corp Life Sciences Running the Slide Rule over SDI SDI was selected in finnCap’s Slide Rule QVGM+ top 30 stocks in Q1 2020, reflecting the projected strong sales and EPS growth over the next two financial years of 30% and 31% respectively, buoyed by recent acquisitions but more importantly the rising ROCE. The prospect of sustainable organic growth is considered likely for this buy-and-build model given ongoing investment to support portfolio companies’ ambitions. These quality metrics are also seen in Judges Scientific (a larger buy-and build investment story), which despite three-year 9% EPS CAGR, trades on a FY 2020 P/E of c.25x and FCF yield of 4.2%. Given the successful acquisition and integration of 11 businesses over the past six years, and mindful of opportunities that still exist for SDI, we are raising our target price to 105p Read Full Thread Follow Reply
27/4/2020 07:24	hastings: Put together the below which may be of interest. Last week saw Cambridge based SDI Group releasing an end of year update to the market, which was, by and large on the day received positively. Indeed, the share price moved northwards, as the company announced that full year 2020 results would be in line with current market forecasts. Of course, as in keeping with other companies now updating or reporting, SDI has understandably withdrawn current market guidance for the financial year ahead which is pretty much to be expected given the as yet, unknown time lines and the potential for disruptance from the Coronavirus. Although as I mention the share price moved forward, some investors clearly exited on Friday, the shares pulling back close to 10% lower at 52p. Some holders appeared to express a nervousness regarding the potential for a collapse in profits for the forthcoming year, whilst others seemed to be expecting an imminent placing. In order to seek some possible clarity on the picture, I once more, as has been customary now since 2013, caught up with CEO Mike Creedon and Chairman Ken Ford. On the issue of a near term placing as some have suggested could be in the offing, Ford dismissed the notion, telling me that they do not currently need to raise cash and referred me to the content of the release. Within that, SDI referred to its sporting a strong balance sheet that holds cash in excess of £4.5m which standing against bank debt of £8.9m looks comfortable enough. Obviously, the current lock down situation brings disruption and uncertainty, but given that we know that the economy is surely going to have to open up sooner rather than later, as a holder of SDI shares I remain comfortable with the statement. As others will know within SDI's broad and diverse interests there is some decent exposure to the health sector along with others supporting that. Creedon informs me that some aspects of the group have been designated as essential businesses and as part of that are involved in providing their customers with components for medical and scientific products used in the fight against COVID-19. There is no inkling as to what these may be involved in, confidentiality playing a part, but it is certainly welcome news that SDI is playing a part in a fight against the virus and that the group remains profitable and cash generative. No doubt some may view the removal of future guidance as a fly in the ointment and have obviously already made their decision on that. However, the team here navigated by Creedon and Ford has done an excellent job over the last five years and under their leadership, I'm happy to stick with the story which remains an attractive one for ongoing growth. Both repeat the acquisition mantra, which not surprisingly remains an important ingredient to future growth here and Creedon says that although there is nothing on the agenda right now, they continue to look. He adds that he is hopeful that there will be a number of acquisitions available at the end of this pandemic. As bad and unwanted as the current lock down situation is, in relation to the former, SDI could find biding its time provides for some decent opportunities further ahead following on from previous excellent acquisitions. Any future buy is likely to be at the smaller end which Creedon confirms will be funded from its own resources as opposed to going back to the market. Looking at the share price graph, SDI has traded in a 52 week range from a 20p low up to a 92p high, which was marked by a sharp retrace to 40p last month, the result of the global market meltdown. It is probably fair to say that the high was very much up with events, whilst the 40p floor provided for an attractive entry point for others who had seemingly missed the boat able to get on board. Right now of course, we are very much dealing with unknowns and uncertainty's where often cool heads are lost in moments of panic and where logic often goes out of the window. From a personal perspective in the case of SDI, I'm happy to hold and await for further developments whilst a further reversal in the share price to the March levels may well provide for another buying opportunity. Each to their own of course, but given Creedon and Ford's belief in continued organic growth progress and the potential for further additions, then SDI surely remains an attractive proposition for the long term. Read Full Thread Follow Reply
06/4/2019 06:40	buywell2: Several months ago buywell suspected that a predator might be lurking taking a look at SDI. SDI was and still is small potatoes to most bigger companies. I urged the BOD on this thread to put 'the pedal to the metal' regarding acquisitions. The reason being let SDI beef itself up ASAP if what I suspected might be true to beef up any offer that might be made. Sensible I think … but the flipside of that is SDI is going to achieve in two years what I thought it would do in three years with the: SDI accelerated strategy for Growth model 4M profits on the way and a Mkt Cap of over 50M … Mkt Cap should be over 60M by this xmas IMO after the next results and further market update/s. Once SDO hit a Mkt Cap of over $100M or over €100M a certain group of predators will take a look … that is the figure that they work with. Likewise certain Fund managers … rules in some have been made that prevent investing until certain market caps are exceeded. I have no qualms about the rate of the acquisitions: a) SDI have been looking at lots of good opportunities over the last couple of years and a list has been made. b) With Brexit now worrying some on the list the price can be negotiated down c) If a company on the list is offered at a bargain price … buy it … before someone else does , a bargain never sits for long. d) Just about every acquisition has had some or most of its management kept in place ie they carry on business as per usual UNTIL SDI works out the improved strategy for growth with them. This could be some new equipment to replace old equipment , more staff to meet orders, developing a new model that needed finance, and most importantly looking at all the cross selling opportunities that have arisen for both the acquisition and other members of the SDI Group. New clients are added to the ever increasing SDI Client list. e) Plus the Distributors and Countries sold into expands yet again so more cross selling opportunities there also. f) SDI BOD are getting very good at this acquisition lark They have it nailed down … it works … success breeds success … they are NOT taking risks by buying a $10M plus company in the USA. They are cherry picking good UK small caps ( ATIK being the exception which turned out a cracker), which are ALL profitable at the time or acquisition and SDI expect to add monies into the SDI pot at the first year of asking. Relax and enjoy the ride as long as it lasts ie till SDI get bought out for a quid a share ie a 40% premium to the share price at the time the offer will be made. dyor GLA Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

SDI

Sdi

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20201204 03:32:20